{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"6"}]}],"title":"Baseline Negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"6"}]}],"title":"Baseline Negative - Negative post-baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"0"}]}],"title":"Baseline Negative - Positive post-baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}],"title":"Baseline Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}],"title":"Baseline Positive - Negative post-baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"Baseline Positive: Treatment-boosted post-baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"groups":[{"description":"Brentuximab vedotin (BV) monotherapy in adults age 60 and above with classical Hodgkin Lymphoma (cHL). BV (1.8 mg/kg) was administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Part A"},{"description":"BV in combination with dacarbazine as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Dacarbazine (375 mg/m\\^2) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG001","title":"Part B"},{"description":"BV in combination with bendamustine as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Bendamustine (70 mg/m\\^2) was administered as an IV infusion on Day 1 and Day 2 of each 21-day cycle.","id":"OG002","title":"Part C"},{"description":"BV in combination with nivolumab as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Nivolumab (3 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG003","title":"Part D"},{"description":"BV as frontline monotherapy in patients with cHL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG004","title":"Part E"},{"description":"BV as frontline monotherapy in patients with CD30-expressing PTCL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG005","title":"Part F"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Subjects with a baseline and at least one post-baseline sample.","reportingStatus":"POSTED","timeFrame":"Up to 30 months","title":"Number of Participants With Brentuximab Vedotin Antitherapeutic Antibodies (ATA)","type":"SECONDARY","unitOfMeasure":"Participants"}